Literature DB >> 23913139

Antibody-drug conjugate target selection: critical factors.

Neil H Bander1.   

Abstract

ADC success requires that all three components of the agent function in a near-flawless manner. Equally important is that the target be selected with stringent consideration as the target is the one factor in ADC development that is immutable and beyond the reach of the developer to refine/manipulate. This chapter reviews the critical factors of target selection that must be met if one is to succeed at ADC development.

Mesh:

Substances:

Year:  2013        PMID: 23913139     DOI: 10.1007/978-1-62703-541-5_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  Antibody-drug conjugates: Intellectual property considerations.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2015-08-20       Impact factor: 5.857

Review 2.  Antibody Drug Conjugates: Preclinical Considerations.

Authors:  Gadi G Bornstein
Journal:  AAPS J       Date:  2015-02-28       Impact factor: 4.009

Review 3.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 4.  The development of potential antibody-based therapies for myeloma.

Authors:  Daniel W Sherbenou; Christopher R Behrens; Yang Su; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 5.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

6.  Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Dario Neri
Journal:  J Control Release       Date:  2016-11-24       Impact factor: 9.776

7.  Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Alberto Dal Corso; Samuele Cazzamalli; Rémy Gébleux; Martin Mattarella; Dario Neri
Journal:  Bioconjug Chem       Date:  2017-07-06       Impact factor: 4.774

8.  A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo.

Authors:  Alberto Dal Corso; Rémy Gébleux; Patrizia Murer; Alex Soltermann; Dario Neri
Journal:  J Control Release       Date:  2017-09-01       Impact factor: 9.776

9.  Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.

Authors:  Rémy Gébleux; Sarah Wulhfard; Giulio Casi; Dario Neri
Journal:  Mol Cancer Ther       Date:  2015-08-20       Impact factor: 6.261

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.